Evolent Q2 revenue up 47% to $469M, raises 2023 Adj. EBITDA guidance; redeems $24.3M convertible notes

Evolent Health, Inc.

2023-Q2 EPS reported -$0.62 revenue$469,136,000

Revenue $469.1M (+46.6% YoY); net loss $41.4M; adjusted EBITDA $47.4M (10.1% margin).
Total Lives on Platform 78.6M (from 19.4M); average unique members 41.8M (from 16.3M).
Signed 2 new operating partners (Molina Florida, regional non-profit) and 2 expansions; YTD 6 deals vs target 6-8.
CEO raises 2023 Adj. EBITDA guidance; reaffirms $300M run-rate target exiting 2024.
Redeeming $24.3M of 3.50% convertible notes due 2024 on Oct 13 for cash (100% principal + interest).

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Evolent Health, Inc. reported the quarter ended June 30, 2023 results: revenue $469.1 million, net income Net loss attributable to common shareholders of Evolent Health, Inc. of $41.4 million. Guidance raised.

Period: the quarter ended June 30, 2023
Revenue: $469.1 million
Net income: Net loss attributable to common shareholders of Evolent Health, Inc. of $41.4 million
Guidance: raised
Result: reported results

Exact text from the filing

simpler and more affordable, today announced financial results for the quarter ended June 30, 2023. Highlights from the second quarter 2023 announcement include: • Revenue of $469.1 million, an increase of $149.2 million, or 46.6%, from the three months ended June 30, 2022. • Net loss attributable to common shareholders of Evolent Health, Inc. of $41.4 million

View on SEC.gov

Browse all earnings releases →

Evolent Health, Inc. filing history →

Source: SEC EDGAR

accession 0001628908-23-000119

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.